Technical Analysis for AKCA - Akcea Therapeutics, Inc.
|Grade||Last Price||% Change||Price Change|
AKCA closed up 3.74 percent on Thursday, July 19, 2018, on 44 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
|See historical AKCA trend table...|
|Date||Alert Name||Type||% Chg|
|Jul 19||Upper Bollinger Band Walk||Strength||0.00%|
|Jul 19||Multiple of Ten Bullish||Other||0.00%|
|Jul 19||Above Upper BB||Strength||0.00%|
|Jul 19||Overbought Stochastic||Strength||0.00%|
|Jul 19||Upper Bollinger Band Touch||Strength||0.00%|
|Jul 18||New Uptrend||Bullish||3.74%|
|Jul 18||Upper Bollinger Band Walk||Strength||3.74%|
|Jul 18||Multiple of Ten Bearish||Other||3.74%|
|Jul 18||Outside Day||Range Expansion||3.74%|
|Jul 18||Above Upper BB||Strength||3.74%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Akcea Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company's drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc. (Ionis). The Company's volanesorsen drug has completed a Phase III clinical program for the treatment of familial chylomicronemia syndrome (FCS) and is currently in Phase III clinical development for the treatment of familial partial lipodystrophy (FPL). The Company's clinical pipeline contains drugs with the potential to treat inadequately addressed lipid disorders beyond elevated LDL-C that are contributing to the dramatic increase in the incidence of cardiometabolic disease, such as elevated triglycerides, oxidized phospholipids and other lipoproteins, such as lipoprotein(a), or Lp(a).
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more AKCA news...
|52 Week High||33.98|
|52 Week Low||12.25|
|200-Day Moving Average||21.9919|
|50-Day Moving Average||24.3548|
|20-Day Moving Average||26.1305|
|10-Day Moving Average||27.098|
|Average True Range||1.7146|
|Chandelier Exit (Long, 3 ATRs )||25.3062|
|Chandelier Exit (Short, 3 ATRs )||28.6738|
|Upper Bollinger Band||29.6861|
|Lower Bollinger Band||22.5749|
|Percent B (%b)||1.08|
|MACD Signal Line||0.7963|
|Market Cap||1.93 Billion|
|Num Shares||63.9 Million|
|Price-to-Earnings (P/E) Ratio||-16.01|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||33.37|
|Resistance 3 (R3)||33.09||31.77||32.85|
|Resistance 2 (R2)||31.77||30.98||31.91||32.68|
|Resistance 1 (R1)||31.01||30.48||31.39||31.29||32.50|
|Support 1 (S1)||28.93||28.90||29.31||29.21||28.00|
|Support 2 (S2)||27.61||28.40||27.75||27.82|
|Support 3 (S3)||26.85||27.61||27.65|
|Support 4 (S4)||27.13|